-+ 0.00%
-+ 0.00%
-+ 0.00%
Neurocrine Biosciences Q3 net income falls to $207 million; Q3 total revenues rise 41% to $1.12 billion
Share
Listen to the news
Neurocrine Biosciences Q3 net income falls to $207 million; Q3 total revenues rise 41% to $1.12 billion
  • Neurocrine Biosciences’ third-quarter 2026 GAAP net income fell to $207 million year over year.
  • Total revenues climbed 41% to $1.12 billion.
  • Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia are expected in 2027.
  • INGREZZA’s full-year 2026 guidance rose to $2.9 billion–$2.93 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000914475-26-000053), on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending